{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T07:54:54Z","timestamp":1794729294690,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z16110000021636"],"award-info":[{"award-number":["Z16110000021636"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chimeric antigen receptor (CAR)-T cell therapy is a powerful adoptive immunotherapy against both B-cell malignancies and some types of solid tumors. Interleukin (IL) -15 is an important immune stimulator that may provide ideal long-term persistent CAR-T cells. However, higher base line or peak serum IL-15 levels are also related to severe toxicity, such as cytokine release syndrome (CRS), graft-versus-host disease (GVHD), and neurotoxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We successfully constructed CD19 specific armored CAR-T cells overexpressing IL-I5 and IL-15 receptor alpha (IL-15Ra). In vitro cell differentiation and viability were monitored by flow cytometry, and an in vivo xenograft mouse models was used to evaluate the anti-tumor efficiency and liver damage of CAR-T cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CAR-T cells overexpressing IL-15 alone demonstrated enhanced viability, retarded exhaustion in vitro and superior tumor-inhibitory effects in vivo. However, these tumor-free mice had lower survival rates, with serious liver injuries, as a possible result of toxicity. As expected, CAR-T cells overexpressing IL-15 combined with IL-15Ra had reduced CD132 expression and released fewer cytokines (IFN\u03b3, IL-2 and IL-15) in vitro, as well as had the tendency to improve mouse survival via repressing the growth of tumor cells and keeping livers healthier compared to CAR-IL-15\u00a0T cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results indicated the importance of IL-15 in enhancing T cells persistence and IL-15Ra in reducing the adverse effects of IL-15, with superior tumor retardation during CAR-T therapy. This study paves the way for the rapid exploitation of IL-15 in adoptive cell therapy in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-022-03626-x","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:10:03Z","timestamp":1664280603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy"],"prefix":"10.1186","volume":"20","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghui","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"3626_CR1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.4049\/jimmunol.168.3.1198","volume":"168","author":"T Yajima","year":"2002","unstructured":"Yajima T, Nishimura H, Ishimitsu R, Watase T, Busch HD, Pamer GE, Kuwano H, Yoshikai Y. Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure. J Immunol. 2002;168:1198\u2013203. https:\/\/doi.org\/10.4049\/jimmunol.168.3.1198.","journal-title":"J Immunol"},{"key":"3626_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/289597","volume":"2011","author":"AL Thompson","year":"2011","unstructured":"Thompson AL, Staats HF. Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol. 2011;2011: 289597. https:\/\/doi.org\/10.1155\/2011\/289597.","journal-title":"Clin Dev Immunol"},{"key":"3626_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/bf01540911","volume":"16","author":"MK Kennedy","year":"1996","unstructured":"Kennedy MK, Park LS. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J Clin Immunol. 1996;16:134\u201343. https:\/\/doi.org\/10.1007\/bf01540911.","journal-title":"J Clin Immunol"},{"key":"3626_CR4","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/j.1460-2075.1994.tb06576.x","volume":"13","author":"JD Giri","year":"1994","unstructured":"Giri JD, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D, Anderson D. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13:2822\u201330.","journal-title":"EMBO J"},{"key":"3626_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s1359-6101(02)00029-1","volume":"13","author":"JP Lodolce","year":"2002","unstructured":"Lodolce JP, Burkett PR, Koka RM, Boone DL, Ma A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 2002;13:429\u201339. https:\/\/doi.org\/10.1016\/s1359-6101(02)00029-1.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3626_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1073\/pnas.0610115104","volume":"104","author":"N Sato","year":"2007","unstructured":"Sato N, Patel HJ, Waldmann TA, Tagaya Y. The IL-15\/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci U S A. 2007;104:588\u201393. https:\/\/doi.org\/10.1073\/pnas.0610115104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3626_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cytogfr.2011.04.001","volume":"22","author":"M Jakobisiak","year":"2011","unstructured":"Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 2011;22:99\u2013108. https:\/\/doi.org\/10.1016\/j.cytogfr.2011.04.001.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3626_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566\u201381. https:\/\/doi.org\/10.1038\/nrc.2016.97.","journal-title":"Nat Rev Cancer"},{"key":"3626_CR9","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Martinez-Lostao","year":"2015","unstructured":"Martinez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21:5047\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0685.","journal-title":"Clin Cancer Res"},{"key":"3626_CR10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720\u20134. https:\/\/doi.org\/10.1073\/pnas.90.2.720.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3626_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181:46\u201362. https:\/\/doi.org\/10.1016\/j.cell.2020.03.001.","journal-title":"Cell"},{"key":"3626_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","volume":"40","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim M, Melief J, Coa\u00f1a YP, Wickstr\u00f6m ST, Cid-Arregui A, Kiessling R. Counteracting CAR T cell dysfunction. Oncogene. 2021;40:421\u201335. https:\/\/doi.org\/10.1038\/s41388-020-01501-x.","journal-title":"Oncogene"},{"key":"3626_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fonc.2020.01143","volume":"10","author":"P Li","year":"2020","unstructured":"Li P, Yang LC, Li T, Bin SF, Sun BH, Huang YT, Yang KY, Shan DM, Gu HH, Li H. The Third generation Anti-HER2 chimeric antigen receptor mouse T cells alone or together with anti-PD1 antibody inhibits the growth of mouse breast tumor cells expressing HER2 in vitro and in immune competent mice. Front Oncol. 2020;10:1143. https:\/\/doi.org\/10.3389\/fonc.2020.01143.","journal-title":"Front Oncol"},{"key":"3626_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong FJ, Zhang C, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13:86. https:\/\/doi.org\/10.1186\/s13045-020-00910-5.","journal-title":"J Hematol Oncol"},{"key":"3626_CR15","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"key":"3626_CR16","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321\u201330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751.","journal-title":"Blood"},{"key":"3626_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/jco.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139. https:\/\/doi.org\/10.1200\/jco.2014.56.2025.","journal-title":"J Clin Oncol"},{"key":"3626_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T cell-associated neurotoxicity. Front Immunol. 2020;11: 577027. https:\/\/doi.org\/10.3389\/fimmu.2020.577027.","journal-title":"Front Immunol"},{"key":"3626_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1161\/strokeaha.119.028638","volume":"51","author":"SX Shi","year":"2020","unstructured":"Shi SX, Li YJ, Shi K, Wood K, Ducruet AF, Liu Q. IL (Interleukin)-15 bridges astrocyte-microglia crosstalk and exacerbates brain injury following intracerebral hemorrhage. Stroke. 2020;51:967\u201374. https:\/\/doi.org\/10.1161\/strokeaha.119.028638.","journal-title":"Stroke"},{"key":"3626_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1182\/blood-2014-06-581793","volume":"125","author":"AK Hechinger","year":"2015","unstructured":"Hechinger AK, Smith BAH, Flynn R, Hanke K, McDonald-Hyman C, Taylor PA, Pfeifer D, Hackanson B, Leonhardt F, Prinz G, et al. Therapeutic activity of multiple common \u03b3-chain cytokine inhibition in acute and chronic GVHD. Blood. 2015;125:570\u201380. https:\/\/doi.org\/10.1182\/blood-2014-06-581793.","journal-title":"Blood"},{"key":"3626_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7150\/jca.48976","volume":"12","author":"D Han","year":"2021","unstructured":"Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current progress in CAR-T cell therapy for hematological malignancies. J Cancer. 2021;12:326\u201334. https:\/\/doi.org\/10.7150\/jca.48976.","journal-title":"J Cancer"},{"key":"3626_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001619","volume":"8","author":"E Wang","year":"2020","unstructured":"Wang E, Cesano A, Butterfield LH. Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy. J Immunother Cancer. 2020;8: e001619. https:\/\/doi.org\/10.1136\/jitc-2020-001619.","journal-title":"J Immunother Cancer"},{"key":"3626_CR23","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123:3750\u20139. https:\/\/doi.org\/10.1182\/blood-2014-01-552174.","journal-title":"Blood"},{"key":"3626_CR24","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget M, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016;113:E7788-e7797. https:\/\/doi.org\/10.1073\/pnas.1610544113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3626_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.cir-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV, Gottschalk S. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5:571\u201381. https:\/\/doi.org\/10.1158\/2326-6066.cir-16-0376.","journal-title":"Cancer Immunol Res"},{"key":"3626_CR26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","volume":"132","author":"J Rossi","year":"2018","unstructured":"Rossi J, Paczkowski P, Shen Y, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132:804\u201314. https:\/\/doi.org\/10.1182\/blood-2018-01-828343.","journal-title":"Blood"},{"key":"3626_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/jco.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803\u201313. https:\/\/doi.org\/10.1200\/jco.2016.71.3024.","journal-title":"J Clin Oncol"},{"key":"3626_CR28","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290\u20137. https:\/\/doi.org\/10.1038\/nm.2446.","journal-title":"Nat Med"},{"key":"3626_CR29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192203","volume":"218","author":"E Lanitis","year":"2021","unstructured":"Lanitis E, Rota G, Kosti P, Ronet C, Spill A, Seijo B, Romero P, Dangaj D, Coukos G, Irving M. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med. 2021;218: e20192203. https:\/\/doi.org\/10.1084\/jem.20192203.","journal-title":"J Exp Med"},{"key":"3626_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/jco.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher AT, Dubois SP, Perera LP, Stewart DM, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33:74\u201382. https:\/\/doi.org\/10.1200\/jco.2014.57.3329.","journal-title":"J Clin Oncol"},{"key":"3626_CR31","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26442","volume":"2","author":"HC Wong","year":"2013","unstructured":"Wong HC, Jeng EK, Rhode PR. The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity. Oncoimmunology. 2013;2: e26442. https:\/\/doi.org\/10.4161\/onci.26442.","journal-title":"Oncoimmunology"},{"key":"3626_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.614667","volume":"11","author":"S Guo","year":"2020","unstructured":"Guo S, Smeltz RB, Nanajian A, Heller R. IL-15\/IL-15R\u03b1 heterodimeric complex as cancer immunotherapy in murine breast cancer models. Front Immunol. 2020;11: 614667. https:\/\/doi.org\/10.3389\/fimmu.2020.614667.","journal-title":"Front Immunol"},{"key":"3626_CR33","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1158\/1535-7163.mct-09-0275","volume":"8","author":"A Bessard","year":"2009","unstructured":"Bessard A, Sol\u00e9 V, Bouchaud G, Qu\u00e9m\u00e9ner A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther. 2009;8:2736\u201345. https:\/\/doi.org\/10.1158\/1535-7163.mct-09-0275.","journal-title":"Mol Cancer Ther"},{"key":"3626_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ijc.29686","volume":"138","author":"D Mathios","year":"2016","unstructured":"Mathios D, Park C, Marcus WD, Alter S, Rhode PR, Jeng EK, Wong HC, Pardoll DM, Lim M. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer. 2016;138:187\u201394. https:\/\/doi.org\/10.1002\/ijc.29686.","journal-title":"Int J Cancer"},{"key":"3626_CR35","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","volume":"180","author":"S Dubois","year":"2008","unstructured":"Dubois S, Patel HJ, Zhang M, Waldmann TA, M\u00fcller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+\/CD44high T cells and its antitumor action. J Immunol. 2008;180:2099\u2013106. https:\/\/doi.org\/10.4049\/jimmunol.180.4.2099.","journal-title":"J Immunol"},{"key":"3626_CR36","doi-asserted-by":"publisher","first-page":"9166","DOI":"10.1073\/pnas.0600240103","volume":"103","author":"MP Rubinstein","year":"2006","unstructured":"Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006;103:9166\u201371. https:\/\/doi.org\/10.1073\/pnas.0600240103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3626_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/eji.200838594","volume":"39","author":"J Rowley","year":"2009","unstructured":"Rowley J, Monie A, Hung CF, Wu TC. Expression of IL-15RA or an IL-15\/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol. 2009;39:491\u2013506. https:\/\/doi.org\/10.1002\/eji.200838594.","journal-title":"Eur J Immunol"},{"key":"3626_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/0008-5472.can-12-2660","volume":"73","author":"MC Ochoa","year":"2013","unstructured":"Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, G\u00farpide A, Prieto J, Pardo J, Berraondo P, et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 2013;73:139\u201349. https:\/\/doi.org\/10.1158\/0008-5472.can-12-2660.","journal-title":"Cancer Res"},{"key":"3626_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nat Rev Clin Oncol. 2021;18:715\u201327. https:\/\/doi.org\/10.1038\/s41571-021-00530-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"3626_CR40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1572-0241.1998.00323.x","volume":"93","author":"OH Nielsen","year":"1998","unstructured":"Nielsen OH, Kirman I, Johnson K, Giedlin M, Ciardelli T. The circulating common gamma chain (CD132) in inflammatory bowel disease. Am J Gastroenterol. 1998;93:323\u20138. https:\/\/doi.org\/10.1111\/j.1572-0241.1998.00323.x.","journal-title":"Am J Gastroenterol"},{"key":"3626_CR41","doi-asserted-by":"publisher","first-page":"11714","DOI":"10.1038\/s41598-019-48046-y","volume":"9","author":"M Vranova","year":"2019","unstructured":"Vranova M, Friess MC, Jahromi NH, Collado-Diaz V, Vallone A, Hagedorn O, Jadhav M, Willrodt A, Polomska A, Lerouxet J, et al. Opposing roles of endothelial and leukocyte-expressed IL-7R\u03b1 in the regulation of psoriasis-like skin inflammation. Sci Rep. 2019;9:11714. https:\/\/doi.org\/10.1038\/s41598-019-48046-y.","journal-title":"Sci Rep"},{"key":"3626_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, Dreger P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.478.","journal-title":"Ann Oncol"},{"key":"3626_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-med-061119-015600","volume":"72","author":"A Schmidts","year":"2021","unstructured":"Schmidts A, Wehrli M, Maus MV. Toward better understanding and management of CAR-T cell-associated toxicity. Annu Rev Med. 2021;72:365\u201382. https:\/\/doi.org\/10.1146\/annurev-med-061119-015600.","journal-title":"Annu Rev Med"},{"key":"3626_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","volume":"38","author":"Y Guo","year":"2017","unstructured":"Guo Y, Luan L, Patil NK, Sherwood ER. Immunobiology of the IL-15\/IL-15R\u03b1 complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017;38:10\u201321. https:\/\/doi.org\/10.1016\/j.cytogfr.2017.08.002.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3626_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.cmet.2016.11.001","volume":"25","author":"M Scheidt","year":"2017","unstructured":"Scheidt M, Zhao Y, Kurt Z, Pan C, Zeng L, Yang X, Schunkert H, Lusis JA. Applications and limitations of mouse models for understanding human atherosclerosis. Cell Metab. 2017;25:248\u201361. https:\/\/doi.org\/10.1016\/j.cmet.2016.11.001.","journal-title":"Cell Metab"},{"key":"3626_CR46","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.ymthe.2020.07.018","volume":"28","author":"L Giuffrida","year":"2020","unstructured":"Giuffrida L, Sek K, Henderson AM, House IG, Lai J, Chen AXY, Todd KL, Petley EV, Mardiana S, Todorovski I, et al. IL-15 Preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors. Mol Ther. 2020;28:2379\u201393. https:\/\/doi.org\/10.1016\/j.ymthe.2020.07.018.","journal-title":"Mol Ther"},{"key":"3626_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu M, Bulsara S. Glypican-3-specific CAR T cells Coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res. 2020;8:309\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0293.","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03626-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:10:20Z","timestamp":1664280620000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03626-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3626"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03626-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Beijing Shijitan Hospital Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}